KRRO — Korro Bio Income Statement
0.000.00%
Last trade - 00:00- $395.83m
- $299.46m
- $2.27m
Annual income statement for Korro Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 2.27 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 35.5 | 59 | 84.5 | 94.2 |
| Operating Profit | -35.5 | -59 | -84.5 | -91.9 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -22 | -58 | -81.1 | -83.4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -22 | -58 | -81.2 | -83.6 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -22 | -58 | -81.2 | -83.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -22 | -58 | -81.2 | -83.6 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -2.74 | -7.25 | -10.1 | -9.37 |